Roche (China) - Academic Profile | RDL Research Database

Publications

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann‐Lii Cheng , Shukui Qin , Masafumi Ikeda +16 more

2021 Journal of Hepatology 1397 citations

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip , Nasser K. Altorki , Caicun Zhou +18 more

2021 The Lancet 1356 citations

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

Yoon‐Koo Kang , Won Ki Kang , D.B. Shin +12 more

2009 Annals of Oncology 766 citations

Affiliated Researchers

Institution Info

Type: company
Country: CN
Publications: 4
Citations: 9,983

External Links

Identifiers

ROR: https://ror.org/02hv5e369

Publications

Affiliated Researchers

Institution Info

External Links

Identifiers

Research Output Over Time